Evidence map›Paper›PMID 41225302›Full record

ArticleDevelopmental medicine and child neurology2026

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study.

Romane Marc, Nicole Chemaly, Mathieu Kuchenbuch, Caroline Espil-Taris, Elodie Lametery, Hélène Maurey, Sylviane Peudenier, Sylvie Nguyen The Tich, Rima Nabbout, Claire Bar

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Developmental medicine and child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Romane MarcDepartment of Paediatric Neurology, Reference Centre for Rare Epilepsies, CHU Bordeaux, Bordeaux, France.ORCID 0009-0005-8088-2684
Nicole ChemalyDepartment of Paediatric Neurology, Reference Centre for Rare Epilepsies, Enfants Malades University Hospital, AP-HP, Université Paris Cité, Paris, France.
Mathieu KuchenbuchUniversité de Lorraine, CHRU-Nancy, Service de Pédiatrie, Reference Centre for Rare Epilepsies, Nancy, France.
Caroline Espil-TarisDepartment of Paediatric Neurology, Reference Centre for Rare Epilepsies, CHU Bordeaux, Bordeaux, France.
Elodie LameteryDepartment of Paediatric Neurology, Grenoble University Hospital, Grenoble, France.
Hélène MaureyDepartment of Paediatric Neurology, Competence Centre for Rare Epilepsies, CHU Bicêtre, Le Kremlin Bicêtre, France.
Sylviane PeudenierPaediatrics Department, CHU Brest, Centre de Référence Déficience Intellectuelle & Polyhandicap de Causes Rares, Brest, France.
Sylvie Nguyen The TichCHU Lille, Reference Centre for Rare Epilepsies, Lille, France.ORCID 0000-0003-4836-0120
Rima NabboutDepartment of Paediatric Neurology, Reference Centre for Rare Epilepsies, Enfants Malades University Hospital, AP-HP, Université Paris Cité, Paris, France.
Claire BarDepartment of Paediatric Neurology, Reference Centre for Rare Epilepsies, CHU Bordeaux, Bordeaux, France.ORCID 0000-0003-1489-0211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the efficacy and tolerability of intravenous immunoglobulin (IVIG) in reducing febrile status epilepticus in children with Dravet syndrome.

methodWe conducted a retrospective multicentre study across seven French university hospitals (2005-2022). Children with genetically confirmed Dravet syndrome who received sequential IVIG were included. Clinical data were collected over two 6-month periods: before and after IVIG initiation.

resultsFourteen individuals (six males, eight females) were included. At IVIG initiation, all were in the stormy phase, aged 10 to 92 months, and receiving a median of four antiseizure medications. IVIG was administered every 1 to 6 weeks (0.3-0.5 g/kg per infusion). Hospitalizations for status epilepticus significantly decreased, from a median of 4 (range 0-16) at baseline to 1 (range 0-6) after treatment (p = 0.002). Twelve individuals improved, two remained stable. Adverse events occurred in 6 out of 14 individuals, including infusion-related fever or seizures. Central venous access was required in six cases. IVIG was continued beyond 6 months in 11 out of 14 individuals.

interpretationThese series suggest a potential benefit of IVIG in reducing status epilepticus in selected children with Dravet syndrome. However, tolerability and feasibility issues were identified. A prospective controlled trial is warranted to further define the role of IVIG in this population.

Indexed as

Epilepsies, MyoclonicImmunoglobulins, IntravenousImmunologic FactorsSeizures, FebrileStatus EpilepticusAnticonvulsantsChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesTreatment OutcomeAnticonvulsantsImmunoglobulins, IntravenousImmunologic Factors

Identifiers

PMID41225302
PMCPMC13160390

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.